In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides
- PMID:1281545
- PMCID: PMC50649
- DOI: 10.1073/pnas.89.24.11823
In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides
Abstract
The c-myb protooncogene encodes proteins that are critical for hematopoietic cell proliferation and development. Disrupting c-myb function might, therefore, prove an effective therapeutic strategy for controlling leukemic cell growth. Antisense oligodeoxynucleotides have been utilized for this purpose in vitro, but their in vivo efficacy has not been reported. We therefore established human leukemia-scid mouse chimeras with K562 cells and treated diseased animals with phosphorothioate-modified antisense oligodeoxynucleotides. K562 cells express the c-myb protooncogene, which served as the target for the antisense DNA. They also express the tumor-specific bcr-abl oncogene that was utilized to track the human cells in the mouse host. Once circulating leukemic blast cells had been detected, the survival of untreated control mice was 6 +/- 3 days (mean +/- SD). The survival of animals treated for 7 or 14 days with either sense or scrambled-sequence c-myb oligodeoxynucleotides was not statistically different from the control animals. In distinct contrast, animals treated for similar lengths of time with antisense c-myb oligodeoxynucleotides survived at least 3.5 times longer than the various control animals. In addition, animals receiving antisense c-myb DNA had significantly less disease at the two sites most frequently manifesting leukemic cell infiltration, the central nervous system and the ovary. These results suggest that phosphorothioate-modified antisense DNA may be efficacious for the treatment of human leukemia in vivo, and by analogy, for the treatment of other human neoplasias.
Similar articles
- Potential therapeutic applications of antisense oligodeoxynucleotides in the treatment of chronic myelogenous leukemia.Gewirtz AM.Gewirtz AM.Leuk Lymphoma. 1993;11 Suppl 1:131-7. doi: 10.3109/10428199309047876.Leuk Lymphoma. 1993.PMID:7504543
- Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.Skorski T, Nieborowska-Skorska M, Wlodarski P, Perrotti D, Hoser G, Kawiak J, Majewski M, Christensen L, Iozzo RV, Calabretta B.Skorski T, et al.J Natl Cancer Inst. 1997 Jan 15;89(2):124-33. doi: 10.1093/jnci/89.2.124.J Natl Cancer Inst. 1997.PMID:8998181
- Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging.Calabretta B, Sims RB, Valtieri M, Caracciolo D, Szczylik C, Venturelli D, Ratajczak M, Beran M, Gewirtz AM.Calabretta B, et al.Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2351-5. doi: 10.1073/pnas.88.6.2351.Proc Natl Acad Sci U S A. 1991.PMID:2006173Free PMC article.
- Oligonucleotide therapeutics: clothing the emperor.Gewirtz AM.Gewirtz AM.Curr Opin Mol Ther. 1999 Jun;1(3):297-306.Curr Opin Mol Ther. 1999.PMID:11713794Review.
- Myb targeted therapeutics for the treatment of human malignancies.Gewirtz AM.Gewirtz AM.Oncogene. 1999 May 13;18(19):3056-62. doi: 10.1038/sj.onc.1202785.Oncogene. 1999.PMID:10378701Review.
Cited by
- Introduction and History of the Chemistry of Nucleic Acids Therapeutics.Gait MJ, Agrawal S.Gait MJ, et al.Methods Mol Biol. 2022;2434:3-31. doi: 10.1007/978-1-0716-2010-6_1.Methods Mol Biol. 2022.PMID:35213007Free PMC article.
- Investigation of the 'n-1' impurity in phosphorothioate oligodeoxynucleotides synthesized by the solid-phase beta-cyanoethyl phosphoramidite method using stepwise sulfurization.Fearon KL, Stults JT, Bergot BJ, Christensen LM, Raible AM.Fearon KL, et al.Nucleic Acids Res. 1995 Jul 25;23(14):2754-61. doi: 10.1093/nar/23.14.2754.Nucleic Acids Res. 1995.PMID:7651837Free PMC article.
- Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts.Sillaber C, Mayerhofer M, Agis H, Sagaster V, Mannhalter C, Sperr WR, Geissler K, Valent P.Sillaber C, et al.Wien Klin Wochenschr. 2003 Aug 14;115(13-14):485-504. doi: 10.1007/BF03041033.Wien Klin Wochenschr. 2003.PMID:13677268Review.
- Requirement of c-Myb for p210(BCR/ABL)-dependent transformation of hematopoietic progenitors and leukemogenesis.Lidonnici MR, Corradini F, Waldron T, Bender TP, Calabretta B.Lidonnici MR, et al.Blood. 2008 May 1;111(9):4771-9. doi: 10.1182/blood-2007-08-105072. Epub 2008 Jan 28.Blood. 2008.PMID:18227349Free PMC article.
- Modeling the Hematopoietic Landscape.Brown G, Ceredig R.Brown G, et al.Front Cell Dev Biol. 2019 Jun 18;7:104. doi: 10.3389/fcell.2019.00104. eCollection 2019.Front Cell Dev Biol. 2019.PMID:31275935Free PMC article.Review.
References
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous